News

This nanohydroxyapatite-based bone graft substitute is said to provide a supporting structure for new bone formation and aid bone healing in places where voids or gaps exists in

In this study, 78% of the 440 patients in the Reyataz /r arm met the primary endpoint of achieving undetectable viral load (defined as HIV-1 RNA less than

Initial in vitro testing conducted by the Provincial Laboratory for Public Health (ProvLab) in Alberta, Canada, showed that Upstream’s potential drug candidates demonstrated anti-malarial activity in the nanomolar

The goal of these studies, which utilized two different dosing regimens, was to further test the ability of Senesco’s Factor 5A technology to induce apoptosis in tumors. Additionally,

The Neuracept trial was a double blind, placebo-controlled study of NP-1 in 215 diabetic peripheral neuropathy (DPN) patients who completed the trial. The data demonstrated that the primary

The final purchase price is subject to adjustment based on the closing net cash balance and working capital of the business and is expected to generate net proceeds,

The US Phase IIa ‘PLUS’ trial will evaluate up to 56 patients with chronic hepatitis C. The PLUS trial will evaluate safety, tolerability, pharmacokinetics and viral kinetics of

Under the agreement, Idera exclusively licensed the therapeutic oncology applications, excluding cancer vaccines, of its lead TLR9 agonists, IMO-2055 and IMO-2125. With the grant of HSR clearance, the

The Center for Devices and Radiological Health (CDRH) received Female Health Company’s (FHC) PMA on January 8, 2008.